600750.SH
华润江中
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 22.52
−8.53%Year over year
Reported trailing growth
- Revenue
- -6.3%
- EBITDA
- —
- EBIT
- +14.5%
- EPS
- +12.7%
- Free cash flow
- -10.1%
- Operating cash flow
- -6.7%
Forward estimates
Based on analyst estimates
- Revenue
- +4.2%
- EBITDA
- +1.7%
- EPS
- +3.2%
Three-year CAGR
- Revenue
- +2.8%
- EBITDA
- +15.8%
- EBIT
- +17.0%
- Net income
- +14.9%
- EPS
- +14.6%
- Free cash flow
- +0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026